Global Recombinant Protein Therapeutics CDMO Market Size- By Type, By Source, By Indication - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Recombinant Protein Therapeutics CDMO Market Introduction and Overview

According to SPER market research, 'Global Recombinant Protein Therapeutics CDMO Market Size- By Type, By Source, By Indication - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Recombinant Protein Therapeutics CDMO Market is predicted to reach 90.1 billion by 2034 with a CAGR of 14.21%.

A recombinant protein therapeutics contract development and manufacturing organization (CDMO) offers specialized services for developing and manufacturing recombinant protein-based therapeutics. These biologic drugs are made by genetically engineering cells to produce therapeutic proteins. CDMOs support pharmaceutical and biotechnology companies with various tailored services.

Restraints: Recombinant Protein Therapeutics are manufactured using highly sophisticated methods that necessitate cutting-edge technology and specialised facilities. To ensure safety, efficacy, and quality, these production stages must comply with severe regulatory requirements. As a result, production costs are far greater than for typical medications. Establishing and maintaining conformity with global regulatory frameworks like the FDA, EMA, and ICH adds to the financial burden.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Type, By Source, By Indication

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Richter-Helm BioLogics, Lonza, Catalent, Inc, FUJIFILM Diosynth Biotechnologies, WuXi Biologics, Curia Global, Inc, Batavia Biosciences B.V, HALIX B.V, BIOVIAN, Enzene Biosciences Ltd.

Global Recombinant Protein Therapeutics CDMO Market Segmentation:

By Type: Based on the Type, Global Recombinant Protein Therapeutics CDMO Market is segmented as; Growth Hormones, Interferons, Vaccines, Immunostimulating Agents, Others.

By Source: Based on the Source, Global Recombinant Protein Therapeutics CDMO Market is segmented as; Mammalian Systems, Microbial Systems, Others.

By Indication: Based on the Indication, Global Recombinant Protein Therapeutics CDMO Market is segmented as; Oncology, Infectious Diseases, Immunological Disorders, Metabolic Disorders, Hematological Disorders, Others.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25148

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2 Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3 Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Recombinant Protein Therapeutics CDMO Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Recombinant Protein Therapeutics CDMO Market

7. Global Recombinant Protein Therapeutics CDMO Market, By Type (USD Million) 2021-2034

7.1. Growth Hormones
7.2. Interferons
7.3. Vaccines
7.4. Immunostimulating Agents
7.5. Others

8. Global Recombinant Protein Therapeutics CDMO Market, By Source (USD Million) 2021-2034

8.1. Mammalian Systems
8.2. Microbial Systems
8.3. Others

9. Global Recombinant Protein Therapeutics CDMO Market, By Indication (USD Million) 2021-2034

9.1. Oncology
9.2. Infectious Diseases
9.3. Immunological Disorders
9.4. Metabolic Disorders
9.5. Haematological Disorders
9.6. Others

10. Global Recombinant Protein Therapeutics CDMO Market, (USD Million) 2021-2034

10.1. Global Recombinant Protein Therapeutics CDMO Market Size and Market Share

11. Global Recombinant Protein Therapeutics CDMO Market, By Region, (USD Million) 2021-2034

11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America

12. Company Profile

12.1. Richter-Helm BioLogics
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Lonza
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. Catalent, Inc
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. FUJIFILM Diosynth Biotechnologies
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. WuXi Biologics
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Curia Global, Inc
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. Batavia Biosciences B.V
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. HALIX B.V
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. BIOVIAN
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Enzene Biosciences Ltd
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Others